SignalCorporate
Codexis reiterates $72M-$76M 2026 revenue outlook while extending cash runway through 2028
Codexis reaffirmed $72M–$76M 2026 revenue guidance and extended cash runway through 2028.
Context
What happened: Codexis reiterated its 2026 revenue guidance of $72M to $76M on its Q3 2026 earnings call and said current cash will fund planned operations and capital expenditures through 2028.
Key numbers: Q3 2026 revenue $19.3M vs $8.6M in Q3 2025. Q3 2026 net loss $8.1M vs $19.6M a year earlier.
Why it matters: Management cited strong pharma biocatalysis performance and sustained gross margin improvement in the first nine months of 2026 as the basis for the raised margin expectation, while expense cuts from lower headcount and reduced outside spending remain a key focus.
Market: -1.9% today ($0.96), -40.5% YTD, 1.1x vol — as of 00:00 UTC
What changed
Codexis reiterated its 2026 revenue guidance of $72M to $76M on its Q3 2026 earnings call and said current cash will fund planned operations and capital expenditures through 2028.
Why it matters
Management cited strong pharma biocatalysis performance and sustained gross margin improvement in the first nine months of 2026 as the basis for the raised margin expectation, while expense cuts from lower headcount and reduced outside spending remain a key focus.
Market: -1.9% today ($0.96), -40.5% YTD, 1.1x vol — as of 00:00 UTC